Biomimetic Electrospun Coatings Increase the In Vivo Sensitivity of Implantable Glucose Biosensors by Wijesuriya, S et al.
Biomimetic electrospun coatings increase the in vivo sensitivity
of implantable glucose biosensors
Krishna Burugapalli,1,2 Shavini Wijesuriya,1,2 Ning Wang,1,2 Wenhui Song3
1Biomedical Engineering Theme, Institute for Environment, Health and Societies, Brunel University London, Uxbridge UB8
3PH, United Kingdom
2Department of Mechanical, Aerospace and Civil Engineering, College of Engineering, Design and Physical Sciences, Brunel
University London, Uxbridge UB8 3PH, United Kingdom
3UCL Centre for Nanotechnology and Regenerative Medicine, Division of Surgery and Interventional Science, University
College London, London NW3 2PF, United Kingdom
Received 16 July 2017; revised 13 October 2017; accepted 5 December 2017
Published online 23 December 2017 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/jbm.a.36308
Abstract: In vivo tissue responses and functional efficacy of
electrospun membranes based on polyurethane (PU) and gela-
tin (GE) as biomimetic coatings for implantable glucose bio-
sensors was investigated in a rat subcutaneous implantation
model. Three electrospun membranes with optimized fiber
diameters, pore sizes, and permeability, both single PU and
coaxial PU-GE fibers and a solvent cast PU film were implanted
in rats to evaluate tissue responses. For functional efficacy test-
ing, four sensor variants coated with the above mentioned
electrospun membranes as mass-transport limiting and outer-
most biomimetic coatings were implanted in rats. The electro-
spun PU membranes had micron sized pores that were not
permeable to host cells when implanted in the body. However,
PU-GE coaxial fiber membranes, having similar sized pores,
were infiltrated with fibroblasts that deposited collagen in the
membrane’s pores. Such tissue response prevented the
formation of dense fibrous capsule around the sensor coated
with the PU-GE coaxial fiber membranes, which helped
improve the in vivo sensitivity for at least 3 weeks compared to
the traditional sensors in rat subcutaneous tissue. Further-
more, the better in vitro sensor’s sensitivity due to electrospun
PU as the mass-transport limiting membrane translated to bet-
ter in vivo sensitivity. Thus, this study showed that electrospun
membranes can play an important role in realizing long in vivo
sensing lifetime of implantable glucose biosensors. VC 2017 The
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INTRODUCTION
Dynamic foreign body reactions on the sensor surface have
been the crucial barrier for the design of reliable, long-term
implantable glucose biosensors.1–5 Specifically, biofouling,
inflammation, fibrosis, receding microvasculature, and
extracellular release of lysosomal contents are responsible
for the unpredictable negative drift in sensor signal.1 How-
ever, from a practical perspective, three main aspects affect
the implanted glucose biosensor function: (1) robustness of
sensor design, (2) biofouling by proteins and cells, and (3)
fluctuation of interstitial fluid levels at implant site.1
Electrochemical glucose biosensors are known to lose
sensitivity as soon as they are implanted followed by a
downward drift until failure. From the sensor design per-
spective, Valdes and Moussy showed that the activity of the
immobilized glucose oxidase (GOD) enzyme is a fundamen-
tal limiting factor in vivo, as it deteriorates due to
accumulation of H2O2 in the sensor element.
6 Moussy et al.
developed a sensor design with a coil reinforced with cotton
that allows loading of excess enzyme as working electrode
to cope with the demands for long-term implantation.7–12
This sensor design provides sensitivities >40 nA/mM,10
which are much better compared to sensors tested earlier,
because current measurements in pA/mM are susceptible to
large fluctuations in vivo.5,13,14
Biofouling significantly lowers the sensitivity of
implanted sensors and its effect at least initially can be
minimized by tailoring surface chemistry of the sen-
sors.1–4,15 However, it cannot stop the eventual adhesion
and spreading of macrophages and foreign body giant cells
on sensor surface that significantly reduce the quantity of
glucose reaching the sensor.5
The tissue microenvironment inherently has much lower
(interstitial) fluid levels compared to in vitro testing in
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simulated body (100%) fluids.16–18 Further, the interstitial
fluid levels at the implant site vary significantly depending
on the stage of inflammation and mechanical disturban-
ces.1–4 Helton et al. also reiterate the role of mechanical
(compressive, tensile, shear and contractile) forces and
micromotion (due to breathing, and pulsing blood vessels),
which chronically disrupt the tissue stabilization during the
natural wound healing process causing unpredictable fluctu-
ations in interstitial fluid levels resulting in erratic sensor
signals.1
Biomaterial coatings can provide the required chemical,
structural and mechanical buffer zone for fulfilling the ulti-
mate goal of long-term implantable glucose biosen-
sors.5,14,19–21 Earlier, we reported electrospun membranes
based on polyurethane (PU) and gelatin (GE) both in single
polymer and coaxial dual polymer formats to coat miniature
glucose biosensors, and systematically characterized their
physical, chemical and mechanical properties, as well as
their effect on sensor sensitivity.10–12 The fibroporous mem-
branes, due to their high pore volume, helped us achieve
significantly higher preimplantation sensor sensitivity com-
pared to the traditional solvent-cast epoxy-PU (EPU) mem-
branes.10,12 Here, we investigate if the higher in vitro
sensitivity translates to that in vivo. Furthermore, Sanders
et al. showed that fiber diameters of 1 to 5.9 lm prevent
fibrous capsule formation around electrospun membranes.22
Hence, we envisaged biomimetic 6PU10GE coaxial fiber
membranes would prevent not only the fibrous capsule for-
mation, but also the barrier cell layer formation at the sen-
sor–tissue interface.
Current study evaluated the tissue responses to four
implant variants: three electrospun membranes namely,
8PU, 12PU, and 6PU10GE (wherein the number prefix indi-
cates the concentration [wt %] of the polymer solution used
to electrospin), and one solvent cast nonporous PU-film
(control). The in vivo functional efficacy of electrospun
membranes in mass transport limiting (8PU) and tissue
engineering (12PU and 6PU10GE) roles on the surface of
implantable glucose biosensors was also assessed. Signifi-
cant findings were that better in vitro sensitivity of sensors
having electrospun membrane for mass transport-limiting
translated to better in vivo sensitivity, and the biomimetic
6PU10GE coatings prevented fibrous capsule formation on
sensor surface, thus improving sensor sensitivity for at least
3 weeks.
MATERIALS AND METHODS
Thermoplastic PU (SelectophoreTM), GE from porcine skin
(type A), tetrahydrofuran (THF), N,N-dimethylformamide
(DMF), bovine serum albumin (BSA), glutaraldehyde (GA)
grade I, 50% and grade II, 25%, GOD (EC 1.1.3.4, Type X-
S, Aspergillus niger, 157 500 U/g; Sigma), ATACS 5104/
4013 epoxy adhesive, Brij 30, D-(1)-glucose, hydrochloric
acid, nitric acid, ammonium hydroxide, neutral buffered
formalin (4%), Mayer’s hematoxylin, Eosin Y, Masson’s Tri-
chrome kit, xylene, and 0.01 M phosphate buffered saline
(PBS) pH 7.4 tablets were purchased from Sigma-Aldrich
(UK). Glacial acetic acid, absolute ethanol, 2,2,2-trifluoroe-
thanol (TFE), and basic histology consumables were pur-
chased from Fisher (UK). Teflon-coated platinum–iridium
(Pt/Ir) (9:1 in weight, Ø 0.125 mm) and silver wires
(Ø 0.125 mm) were obtained from World Precision
Instruments (Sarasota, FL). Sprague Dawley rats (Harlan
UK, Oxon, UK) weighing between 175 and 200 g were
housed in the experimental animal facility at Brunel Uni-
versity. All animal procedures had ethical approval from
the ‘Animal Welfare Ethical Review Board’ of Brunel Uni-
versity and covered under the appropriate project (PPL
No. 70–6993) and personal (PIL No. 70–21528) licenses
from Home Office, UK. Home office, UK guidelines for the
care and use of laboratory animals (Animals [Scientific
Procedures] Act 1986) were observed. Isofluorane (ISO-
FloV
R
), ketamine hydrochloride (Ketaset), xylazine (Chana-
zine), buprenorphine hydrochloride (Vetergesic), soft
paraffin (Lacri-lube), atipamezole hydrochloride (ATIPAM),
sodium pentobarbitone (Euthatal), and carprofen
(RIMADYL) were supplied by Lab Services (London, UK).
EthiconTM 5–0 Polygalactin and Prolene (Johnson & John-
son) sutures were purchased from Vet Tech Solutions
(Cheshire, UK). Surgical consumables were purchased
from Barrier Healthcare (Lincolnshire, UK). ALPHELYS
RCL-2 formalin-free fixative was purchased from Mitogen
(UK). Abbott FreeStyle Lite blood glucose meter and test
strips were purchased from Point Pharmacy (UK). Medical
oxygen cylinders were supplied by Air Liquide UK. Deion-
ized water purified using a Barnstead water purification
system was used for all experiments.
Electrospinning single and coaxial fiber membranes
The methods for traditional and coaxial electrospinning of
PU and PU-GE (coaxial) fiber membranes both on static
plate collector and directly on the miniature sensor surface
using a dynamic collector were presented in our earlier
reports.10–12 The materials and parameters for electrospin-
ning are summarized in Table I.
Sensor preparation and designations
The method for sensor manufacture was described in our
previous reports, except that the Pt-Ir working electrode
coil in this study had an additional interference reducing
layer.10,23 The bare cotton-reinforced Pt-Ir coil was coated
with a polyphenylenediamine layer by electropolymeriza-
tion at 0.7V versus standard calomel electrode in a PBS
containing 5 mM phenylenediamine, 20 U/mL GOD, and
1 lL/mL 0.25% GA.7,10,23 Figure 1 shows the schematic
representation of the sensor design and function as well
as the scanning electron microscopy (SEM) images show-
ing the cross-section of the sensors tested in this study.
The typical working electrode had a cotton reinforced Pt/
Ir coil (designated as Pt) coated with GOD immobilized
on BSA using GA crosslinking. The base Pt-GOD sensors
were coated with either EPU or electrospun 8PU mem-
branes. The respective sensors were designated as Pt-
GOD-EPU and Pt-GOD-8PU. To test the efficacy of
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electrospun membranes as tissue engineering sensor sur-
face coatings, two membrane configurations, namely, 12PU
and 6PU10GE were used. The four sensor configurations
tested for in vivo functional efficacy were Pt-GOD-EPU, Pt-
GOD-8PU-12PU, Pt-GOD-EPU-12PU, and Pt-GOD-EPU-
6PU10GE (Table I).









Biocompatibility testing (1 3 1 cm2 sheets)
PU film n/a n/a n/a
8PU Static; 22G needle 8% PU in 40:60 w/w THF:DMF 21 kV; 0.6 mL/h; 22 cm
12PU Static; 22G needle 12% PU in 50:50 w/w THF:DMF 20 kV; 1.2 mL/h; 22 cm
6PU10GE Static; 21G core/10G
shell coaxial needle
6% PU in TFE (core) and 10%
GE in TFE (shell)
13.25 kV; 0.8 mL/h (core) and
1.2 mL/h shell; 15 cm
In vivo functional efficacy testing of implantable continuous glucose monitoring sensors
Pt-GOD-EPU n/a n/a n/a
Pt-GOD-8PU-12PU Dynamic; 22G needle 8% PU in 40:60 w/w THF:DMF
followed by 12% PU in 50:50
w/w THF:DMF
21 kV; 0.6 mL/h; 22 cm fol-
lowed by 20 kV; 1.2 mL/h;
22 cm
Pt-GOD-EPU-12PU Dynamic; 22G needle 8% PU in 50:50 w/w THF:DMF 20 kV; 1.2 mL/h; 22 cm
Pt-GOD-EPU-6PU10GE Dynamic; 21G core/10G
shell coaxial needle
6% PU in TFE (core) and 10%
GE in TFE (shell)
13.25 kV; 0.8 mL/h (core) and
1.2 mL/h shell; 15 cm
aAmbient temperature and humidity for all electrospinning was 20 6 28C and 40 6 5%, respectively.
FIGURE 1. The design of the amperometric sensor used in this study. (a) A schematic representation of the sensor design and function; inset—
light microscopy photo to illustrate the size of the working electrode, (b, c) scanning electron microscopy images showing the cross-section of
the sensors, wherein 1 is cotton, 2 is Pt-Ir coil, 3 is GOD immobilized on BSA using GA crosslinking, 4 is EPU mass transport limiting mem-
brane, 5 is electrospun membrane as tissue engineering coating, and 6 is electrospun membrane as mass transport limiting membrane, (c)
inset—SEM image showing surface porosity of electrospun coating on sensor.
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Crosslinking of GE
The GE in the 6PU10GE coaxial fibers of the electrospun
sheets or coatings on sensors was stabilized by GA cross-
linking in a GA vapor environment in a vacuum desiccator
with the desiccant replaced by 10 mL of 25% aqueous GA
solution for three days.
Sensor calibration and testing
Preimplantation sensitivity of the test sensors was meas-
ured using Apollo 4000 Analyser (World Precision Instru-
ments, Sarasota, FL).10 Sensors were equilibrated in PBS at
an applied voltage of 0.7V between the Pt-Ir working elec-
trode and the Ag/AgCl reference electrode, while continu-
ously stirring the PBS solution. Calibration plots for the
sensors were obtained by measuring current while increas-
ing the glucose concentration (0–30 mM). The sensitivity
(S) of each sensor was calculated using the equation:
S5 I152 I5mMð Þ=10
where I15 and I5 mM are the steady state currents for 15
and 5 mM glucose concentration, respectively.
Tissue response evaluation
The tissue responses to the test membranes (1 3 1.5 cm2
sheets) were evaluated using male Sprague Dawley rats
acclimatized to local environment for 1 week prior to sur-
gery. The rats were anaesthetized with ketamine (80 mg/kg)
and xylazine (10 mg/kg) and eyes lubricated with Lacri-lube.
Subcutaneous injections of 0.05 mg/kg buprenorphine
hydrochloride and 10 mg/kg carprofen were used as analge-
sics. The dorsal skin was shaved and disinfected with iodine.
Along the dorsal midline, three 1.5 cm longitudinal incisions
were made, about 3 cm apart. At each incision, two lateral
subcutaneous pockets were made. In each pocket one test
membrane was inserted at the subcutaneous level about
1 cm away from the incision. Prior to implantation, the differ-
ent scaffolds were sterilized by their incubation in 70% etha-
nol for 1 h followed by washing in several changes of sterile
saline. The incisions were closed using a degradable Ethi-
conTM 5–0 Polygalactin. Following implantation, atipamezole
hydrochloride was administered for reversal of the sedative
effects of xylazine. The rats were given standard pellet diet
and fresh water. The implant sites were physically observed
at regular intervals. A total of six rats were divided into two
groups of three each. Four implant variables: PU film, 8PU,
12PU, 6PU10GE were assessed in this study. Per time point,
three samples of each implant variable were implanted. The
two groups of rats were sacrificed after 4 and 9 weeks,
respectively, and subsequently the implant sites were har-
vested and fixed in RCL-2 formalin free fixative.
Histology
RCL-2 fixed tissues were dehydrated through graded ethyl
alcohol solutions (70, 95, and 100%), cleared with xylene
and embedded in paraffin. Seven-micrometer thick paraffin
sections were stained with hematoxylin and eosin (H&E),
and Masson’s trichrome (MT). The stained sections were
observed under light microscope and digital images were
captured using SP-500 POL microscope equipped with Mini-
cam DCM 1.3M USB 2.0 digital camera (Brunel Microscopes,
Bristol, UK).
Subcutaneous implantation of glucose sensors
Sensor configurations Pt-GOD-8PU-12PU, Pt-GOD-EPU-12PU,
Pt-GOD-EPU-6PU10GE, and Pt-GOD-EPU (n5 6 for each con-
figuration) were implanted in 12 rats. The method was simi-
lar to that described above for implantation of membranes in
subcutaneous tissue. However, each rat received two sensors
and the incisions were done perpendicular to the axis of dor-
sal midline over the shoulder blade. In each pocket, the sen-
sor was inserted parallel to the dorsal midline and the
sensing electrodes away from the neck and the leads exiting
skin close to the neck. For implantation, the sensors were
reinforced with silicon tubing (U1/16’) leaving electrodes
and leads at either end uncovered. A knot was then made in
the middle section covered with silicone tubing and either
ends of the silicon tubing sealed using epoxy resin (ATACS).
During implantation, the knot was threaded with a nonde-
gradable EthiconTM ProleneV
R
suture and immobilized in the
subcutaneous tissue, such that the leads exited to exterior at
the incision in the skin. The incision in the skin was then
closed using a degradable Ethicon 5–0 Polygalactin.
In vivo functional efficacy testing of glucose sensors
Sensor testing was performed at 1, 3 and 9 weeks after
implantation on each rat. Anesthesia was induced and main-
tained either by intraperitoneal (IP) injection of sodium
pentobarbitone or by inhalation of isoflurane to test the
effect of anesthesia on blood glucose levels. With pentobar-
bitone, anesthesia was induced by IP injection of 0.2 mL of
50 mg/mL pentobarbitone and then maintained by a further
3 to 4 injections of 0.1 mL 50 mg/mL pentobarbitone at
approximately, 20, 50, 80, 140 min, and 0.5 to 1 L/min oxy-
gen supplied continuously through a mask. With isoflurane,
anesthesia was induced first by placing the rat in a plexi-
glass chamber and flowing isoflurane and oxygen at 2.5%
and 1 L/min, respectively, through the chamber and then
transferring the anesthetized rat on to a heated mat, a mask
fitted and flowing 1% isoflurane and 0.5 to 1 L/min oxy-
gen to maintain anesthesia for the duration of the testing.
Buprenorphine hydrochloride and carprofen were adminis-
tered for analgesia. Within 15 to 20 min of induction of
anesthesia, the sensors were connected to the Apollo 4000
Analyzer to log the change in current as a function glucose
concentration at an applied potential of 0.7V. Once the base-
line current was established, an IP injection of 0.7 mL of
50% glucose in saline (1 mg/kg). Blood glucose concen-
tration were also measured at 5 min intervals using a
commercial glucose monitor—Freestyle Lite by withdrawing
blood drops from an incision made at the tip of rat’s tail.
The tests typically took 2 h and 196 16 min. The in vivo
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where, DI is the difference of current between the peak and
the baseline, and DC the corresponding difference in con-
centration of blood glucose as measured with commercial
glucometer. Following the third functional efficacy test at 9
weeks after implantation, the rats were euthanized with a
1 mL IP injection of 200 mg/mL pentobarbitone. The sensor
implant sites were harvested, fixed in RCL-2 fixative, and
processed for histopathology.
Statistical analysis
Statistical analyses were carried out using IBM SPSS (v.20)
statistical software. Statistical variances between groups
were determined by analysis of variance. Tukey’s test was
used for post hoc evaluation of differences between groups.
A p<0.05 was considered statistically significant. All data is
presented as mean6 standard error of mean.
RESULTS AND DISCUSSION
Reproducible production of transmembrane interconnectiv-
ity of pores, high pore volumes and uniform thickness
proved useful with electrospun PU as mass-transport limit-
ing membranes for glucose biosensors.10,11 Electrospun
membranes are also widely researched and utilized as tis-
sue engineering scaffolds.24 In this study, we investigated
the role of electrospun membranes as both mass-transport
limiting and tissue engineering coatings to prolong the in
vivo sensing lifetime of implantable glucose biosensors.
The properties of the membranes tested in this work
are summarized in Table II.10–12 8PU, 12PU, and 6PU10GE
membranes had average fiber diameters and average pore
sizes of 0.347, 1.102, and 1.15 mm, and 0.8, 1.06, and 1.54
mm, respectively. Further, the membranes had average elas-
tic moduli of 2300, 970, and 930 kPa, respectively, which
are higher compared to the 2.75 to 240 kPa range reported
for rat subcutaneous and skin tissue.25
Tissue reactions to electrospun membranes implanted
in subcutaneous tissue
Gross morphology. Following surgery, all rats recovered
normally and survived the duration of the experiments. The
incision and implant sites did not show any ulceration, pus,
discharge or infection. No obvious swelling of the implants
sites was visible.
Histopathology. Histologically, all the scaffolds were intact
until the end of study at 9 weeks. Figure 2(a,b) show the
histology of subcutaneous tissue structure on the nonporous
TABLE II. Properties of the Electrospun Membranes Implanted in the Subcutaneous Space in Rats11,12
8PU 12PU 6PU10GE PU Filma
Fiber diameter (mm) 0.347 6 0.087 1.102 6 0.210 1.15 60.13 -
Thickness (mm) 23.5 6 4.8 133.0 6 28.3 44.5 6 2.2 71.6 6 16.8
Pore volume (%) 44.19 6 2.54 65.40 6 1.85 63.33 6 1.34 -
Pore size (mm) 0.80 1.06 1.54 -
Contact angle 104.38 122.58 08 868
Young’s Modulus (MPa) 2.3 6 0.85 0.97 6 0.049 0.93 6 0.14 2.8 6 0.43
UTS (MPa) 5.8 6 2.13 3.1 6 0.06 1.83 6 0.22 8.1 6 2.00
Strain at break (%) 191.2 6 61.10 261.0 6 12.09 133.29 6 7.17 849.7 6 258.8
aNonporous solvent cast PU film was used as the control.
FIGURE 2. Light microscopy images showing H&E stained subcutane-
ous tissue above the PU film implant following 4 weeks of implanta-
tion (a) and its magnified section (b) and 9 (c), where M is
subcutaneous smooth muscle, NF is native fibrous tissue, F is fibrous
tissue (capsule) surrounding the implant I.
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PU film implant (I) surface at 4 weeks after implantation.
About three cell-layers’ thick fibrous capsule (F) was
observed on the implant surface. Between the dense fibrous
tissue and the subcutaneous smooth muscle (M) layers was
a thick layer of typical subcutaneous native fibrous (NF) tis-
sue. Several blood capillaries/vessels were also seen at the
interface between the NF tissue and the dense fibrous tissue
surrounding the implant. At 9 weeks [Fig. 2(c)], the fibrous
capsule became thicker (100 mm). The cells in the fibrous
tissue were primarily fibroblasts (spindle shaped cells each
with a oval shaped active nucleus) at 4 weeks, while at 9
weeks majority of the fibroblasts changed into fibrocytes
(inactive fibroblasts, containing thin and long nucleus hav-
ing inactive condensed genetic material).26 No immune cells
were observed in the fibrous tissue surrounding the PU
films, indicating the inert nature of the PU material.
Electrospinning introduced fibro-porous structures in
8PU and 12PU membranes. However, when they were
implanted in the body, their pore sizes were too small
(1 lm) to allow infiltration of cells into the bulk of the
membranes. Hence, the tissue responses to both 8PU and
12PU were like that observed for nonporous PU film at
both time points (Fig. 3). The small pore sizes can be attrib-
uted to the nature of deposition of fibers by electrospinning.
The fibers fuse at contact points with neighboring fibers
resulting in a rigid fibrous mesh.27,28
However, 6PU10GE coaxial fiber membranes, having simi-
lar pore size (1.5 mm), allowed host cell infiltration into its
fibro-porous bulk (Fig. 4). The immediate surface of the host
cell infiltrated 6PU10GE membrane, unlike that of 8PU and
12PU, was not covered by dense fibrous encapsulation. But,
the cell content in this layer was significantly higher, with pri-
marily macrophages indicating an active resorption of GE
[Fig. 4(a–d)]. Some lymphocytes were also observed
indicating a mild immune response to GE, which could further
accelerate resorption of GE. The blue staining in the MT
stained histology sections is collagen. At 4 weeks, hardly any
blue staining was seen within the 6PU10GE membrane [Fig.
4(b)]. But by 9 weeks, collagen deposition was seen within
the 6PU10GE implant matrix [Fig. 4(d)]. GE, being an extrac-
ellular matrix (ECM) derivative, is susceptible to enzymatic
degradation, and its resorption would make the thin PU cores
discreet and flexible allowing movement of cells within the
scaffold. The tiny darkly stained structures within the scaffold
indicate cells attached to the individual electrospun fibers
along the fiber axis [Fig. 4(a,c)]. Such cell adhesion to fibers
also indicates that the cells are fibroblasts. Occasional pres-
ence of larger cells within the scaffold was also indicative of
infiltration of larger cells (10 mm) through displacement of
flexible fibers. This result demonstrates that the rigidity due
to fusion of neighboring fibers can be overcome by using a
degradable coating on the electrospun fiber surface [Fig. 4(a–
d)]. Zhang et al. also reported partial cellular infiltration into
electrospun membranes having fiber size around 1 lm in an
in vitro cell culture study for composite fibers that were elec-
trospun with blended solutions of polycaprolactone and GE.29
In vivo functional efficacy testing
Following surgery for implantation of sensors, all rats recov-
ered normally and survived the duration of the experiments
(9 weeks) without any adverse events at the implants sites.
The rats weighed 2576 18 g at the time of sensor implanta-
tion, and gained weight consistently, with average weights
of 2966 25, 3316 24 and 3786 30 g at 1, 3 and 9 weeks,
respectively.
Effect of anesthesia on blood glucose levels. Glucose toler-
ance test provides a means to verify the functional efficacy
FIGURE 3. Light microscopy images showing the tissue-implant interface for: (a, b) 8PU and (c, d) 12PU; at (a, c) 4 weeks and (b, d) 9 weeks of
implantation; (a, d) [MT stained and (b, c)] H&E stained sections, where A is subcutaneous fat (adipose), F is fibrous tissue (capsule) surround-
ing the implant I.
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of sensors implanted for continuous glucose monitoring.
However, such testing, in the absence of wireless means of
logging the sensor output, requires the use of general anes-
thesia. Anesthetics, in turn, are known for their effect on
disruption of glucose homeostasis, and depression of respi-
ratory and cardiovascular systems. Here, we compared pen-
tobarbitone and isoflurane for their effects on blood glucose
levels. Pentobarbitone did not affect the blood glucose lev-
els, but isoflurane consistently induced hyperglycemia
(Fig. 5). Similar results are widely reported.14,30–33 In a sim-
ilar study, Koschwanez et al. tested the effect of isoflurane
and pentobarbitone on blood glucose levels, and used pen-
tobarbitone since it did not cause hyperglycemia for sensor
functional efficacy testing.14 They administered a single IP
dose of 0.3 mL of 50 mg/mL pentobarbitone (Nembutal
Sodium Solution). However, we observed repeated dosing
with lower volume of pentobarbitone to be safer at main-
taining anesthesia, because the margin between anesthetic
and lethal doses for pentobarbitone is very narrow.34 How-
ever, concerns are raised because of the low pH of the pen-
tobarbitone solution.35 Due to pain that may be caused by
the low pH, use of pentobarbitone as an anesthetic is gener-
ally discouraged unless it was for nonrecovery procedures.
Similarly, the use isoflurane as an anesthetic for glucose tol-
erance test is discounted since it offsets the glycemic profile.
Despite the offset, we noticed the glycemic profile was com-
parable to that observed with pentobarbitone [Fig. 5(b,c)].
However, it was also shown that the effect of hyperglycemia
induced by isoflurane can be minimized using analgesia.32,33
We used buprenorphine hydrochloride and carprofen as
analgesics to obtain baseline blood glucose levels of
6.5260.28 and 4.4560.1 mM/L for isoflurane and pento-
barbitone, respectively.
Upon IP injection of glucose (1 g/kg), blood glucose
levels rose rapidly, peaked at 8.876 0.45 mM/L and
13.236 0.53 mM/L, respectively, for pentobarbitone and
isoflurane and tailed off slowly [Fig. 5(a)]. For isoflurane, it
took longer for glucose levels to peak and longer to
decrease. The difference can be attributed to the continuous
dose of isoflurane for maintaining anesthesia. Despite the
baseline increase of blood glucose levels with the use of iso-
flurane, the dynamics of blood glucose levels as measured
by the implanted sensor response current was similar to
that measured using the commercial blood glucometer [Fig.
5(c)], which dynamic change in blood glucose levels was
also similar to that observed with pentobarbitone [Fig.
5(b)]. Thus, with appropriate analgesia, isoflurane can serve
as an anesthetic for glucose tolerance tests in healthy rats.
Effect of electrospun coatings on the function of glucose
biosensors implanted in the subcutaneous tissue of
rats. The sensor configurations Pt-GOD-8PU-12PU, Pt-GOD-
EPU-12PU, Pt-GOD-EPU-6PU10GE, and Pt-GOD-EPU were
tested for functional efficacy in vivo at 1, 3 and 9 weeks
after implantation for each implanted sensor. Examples of
typical sensor response current curves measuring glucose
levels in interstitial fluid as a function of time along with
the corresponding change in blood glucose levels are shown
in Figure 5(b,c). The sensor response delay was calculated
in relation to changes of glucose level in blood as indicated
in Figure 5(b,c).
Premature sensor failure is quite common in implant-
able glucose monitoring. In this study, 4, 5, 2, and 3 out of
6 sensors were functional at the end of the study period of
9 weeks for Pt-GOD-EPU, Pt-GOD-8PU-12PU, Pt-GOD-EPU-
12PU, and Pt-GOD-EPU-6PU10GE sensors, respectively. 2
and 1 sensors failed by 3 weeks for Pt-GOD-EPU and Pt-
GOD-8PU-12PU, respectively. On the other hand, 2 of the 4,
and 2 of the 3 nonfunctional sensors in the case of Pt-GOD-
EPU-12PU and Pt-GOD-EPU-6PU10GE, respectively, could
FIGURE 4. Light microscopy images showing the implant sites for 6PU10GE (a) H&E and (b) MT stained sections at 4 weeks after implantation,
and (c) H&E and (d) MT stained section at 9 weeks after implantation, where NF is the native fibrous tissue structure, and I the implant.
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not be tested due to broken sensor leads. Of the four func-
tional Pt-GOD-EPU-12PU sensors implanted in the rat sub-
cutaneous tissue, two failed by 9 weeks, and of the four
functional Pt-GOD-EPU-6PU10GE sensors, one failed by 3
weeks. Essentially, at least 50% of the sensors were func-
tional till the end of the 9-week study period, which can be
attributed to the larger quantity of glucose oxidase immobi-
lized on the cotton-reinforced coil of the working electrode
design tested in this study (Fig. 1). Similar correlation of
higher levels of GOD loading leading to longer in vivo sens-
ing life was reported earlier.6
Sensor response delay. The time taken for the implanted
glucose biosensors to respond to the high dose of glucose
injected in the peritoneum was compared with that in blood
and results presented in Figure 6(a). At week 1 after
FIGURE 5. Change in blood glucose concentration: (a) measured
using Freestyle Lite blood glucose meter showing the effect of two
types of anesthesia on blood glucose levels, (b, c) The typical sensor
response current vs. time plot of an implanted sensor and the corre-
sponding change in blood glucose levels measured using a commer-
cial blood glucose monitor for rats. The anesthesia used for the rats
in b and c were sodium pentobarbitone (n 5 16) and isoflurane
(n 5 17), respectively. The blue arrow indicates time of injection of a
high dose of glucose in the peritoneum. The sensor response delay
for the coil-type glucose biosensor implanted in subcutaneous tissue
compared to the corresponding change in blood glucose level is indi-
cated by the double end arrow (b, c).
FIGURE 6. In vivo sensor performance: (a) delay in response to sens-
ing glucose in interstitial fluid for coil-type glucose biosensors
implanted in the subcutaneous tissue in relation change in blood glu-
cose levels as a function of sensor coating configurations; (b) change
in sensitivity of glucose biosensors implanted in the subcutaneous tis-
sue of rats; and (c) change in sensitivity of glucose biosensors
implanted in the subcutaneous tissue of rats normalized to their pre-
implantation sensitivities.
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implantation, Pt-GOD-8PU-12PU sensors showed the fastest
response to glucose (<10 min), followed by Pt-GOD-EPU-
6PU10GE and then Pt-GOD-EPU-12PU. The control sensor
Pt-GOD-EPU showed the slowest response time of 15 min.
By 3 weeks of implantation, Pt-GOD-EPU sensors showed
the fastest response time, while that for other sensors with
electrospun coatings increased. The trend at week 9 was
comparable with that at week 3, except that the sensor Pt-
GOD-EPU-6PU10GE showed a decrease in sensor response
time. This decrease resulted in its sensor response time to
be on par with that of the control sensor Pt-GOD-EPU. The
changes in response times could be indicative of the nature
of changes in composition of tissue at the sensor tissue
interface. The high pore-volume of the electrospun mem-
branes at week 1 could be responsible for their better per-
meability to glucose and hence faster response time.11
However, at week 3, the tissue build-up at their surface
could be responsible for the increase in sensor response
delay time. In contrast, the control Pt-GOD-EPU sensor
showed initial slower response to glucose which could be
due to poor wetting of its EPU membrane, compared to the
fluid filled pores of electrospun membranes. The wetting
could have improved with deposition of snugly fit host tis-
sue on the EPU membrane, thus lowering the sensor
response time thereafter. The sensor response time for Pt-
GOD-EPU-6PU10GE decreasing to the level observed with
Pt-GOD-EPU control sensor could be due to the resorption
of Ge-shell and replacement with collagenous connective tis-
sue similar to that observed with PU films.
Sensitivity of implanted biosensor to glucose. The preim-
plantation in vitro sensitivity was 46.1365.36, 22.886 4.31,
24.216 3.76, 15.906 2.40 nA/mM, respectively, for Pt-GOD-
8PU-12PU, Pt-GOD-EPU, Pt-GOD-EPU-12PU, and Pt-GOD-EPU-
6PU10GE [Fig. 6(b)], which sensitivities are significantly
higher than the 3.5646 0.054 nA/mM reported by Koschwa-
nez et al. for Medtronic MiniMed SOF-SENSORTM glucose sen-
sors.14 The higher sensitivities for our sensors can be
attributed to larger quantity of GOD loaded on the working
electrodes. Furthermore, among the sensors tested in this
study, replacing the traditional solvent cast EPU with electro-
spun 8PU as the mass-transport limiting membrane more
than doubled the in vitro sensitivity. Earlier, when we tested
8PU as the mass transport limiting membrane, the sensitivity
increased by about 30% compared to that without a mass
transport limiting membrane (Pt-GOD).10 In contrast, the cor-
responding change for the traditional EPU mass transport
limiting membrane was about 10% decrease. This difference
manifested as more than double the sensitivity for Pt-GOD-
8PU-12PU compared to Pt-GOD-EPU in this study. This can be
attributed to an ordered and gradient transmembrane poros-
ity across the 8PU-12PU electrospun coatings on the Pt-GOD
sensor surface.
As expected, the sensitivity for all sensor configurations
decreased with increasing implantation time [Fig. 6(b)]. But,
it was interesting to note that the higher the preimplanta-
tion sensitivity the higher was the sensitivity in vivo, as
observed with Pt-GOD-8PU-12PU sensors. Larger the meas-
ured sensor response currents, the lesser will be the signal-
to-noise ratio. However, when the in vivo sensitivities of the
different sensors were normalized to their corresponding
preimplantation sensitivities, the percent decrease in sensi-
tivity was similar for all sensors. This proportional decrease
in sensor sensitivities with time is indicative of the deactiva-
tion of the immobilized GOD on the sensor’s working elec-
trodes as reported by Valdes and Moussy,6 which is further
reiterated by our result that >50% of the implanted sensors
were functional at 9 weeks after implantation. Koschwanez
et al. showed that majority of the Medtronic MiniMed SOF-
SENSOR
TM
glucose sensors (with lower preimplantation sen-
sitivities compared to sensors tested in our study) failed to
respond to the glucose bolus within 2 weeks and all sensors
failed by 3 weeks.14
When bioactive 6PU10GE coaxial fiber membranes were
used as the tissue engineering coatings on the traditional
Pt-GOD-EPU sensors, the percent decrease in sensitivity was
slowest in vivo when compared to the rest of the sensors
both at 1 and 3 weeks after implantation [Fig. 6(c)], which
can be credited to the prevention of dense fibrous capsule
on 6PU10GE surface. However, at 9 weeks the advantage of
6PU10GE coatings was lost due to resorption of GE and
replacement with collagen, resulting in sensitivities similar
to the traditional Pt-GOD-EPU sensors.
CONCLUSION
Fibro-porous structure of electrospun membranes with
average pore sizes of 1 mm did not influence the nature of
tissue responses compared to nonporous solvent-cast PU
film. However, the bioactive 6PU10GE coaxial fiber mem-
branes, also having similar pore size (1.5 mm), allowed
host cell infiltration into its fibro-porous bulk. As mass
transport limiting membranes, electrospun 8PU membranes
showed higher preimplantation in vitro sensitivity, which
translated to higher in vivo sensitivity. Furthermore, the bio-
mimetic 6PU10GE coating prevented fibrous capsule forma-
tion on sensor surface, thus increasing sensor sensitivity for
at least 3 weeks. To conclude, electrospun membranes can
replace traditional mass-transport limiting membranes as
well as function as tissue engineering outer coatings to reli-
ably prolong the in vivo sensing lifetime of implantable glu-
cose biosensors.
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